Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melanoma
20 August 2026
No Comments
RAHWAY, N.J. and CAMBRIDGE, MA, August 19, 2026 – Merck (NYSE: MRK), known as